Physician profile
Wei Bin
NPI 1619135043
$6,693.89
in general payments reported to CMS, 2019-2025
30 companies · $305 in 2025
The $305 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,489 · 2020: $727 · 2021: $609 · 2022: $1,249 · 2023: $1,405 · 2024: $909 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,619.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,696.61 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,325.70 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Harmony Biosciences LLC | $615.54 | 2021-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $492.70 | 2019-2024 | Spiriva Respimat, Ofev |
| Genzyme Corporation | $418.70 | 2019-2025 | |
| Insmed, INC. | $302.28 | 2019-2024 | Arikayce |
| Philips North America LLC | $252.53 | 2019-2024 | (Ak6) Vest Therapy |
| Mylan Specialty L.P. | $221.50 | 2019-2023 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $206.78 | 2019-2025 | Dupixent |
| Allergan, INC. | $166.29 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $140.37 | 2019-2024 | |
| Grifols USA, LLC | $85.74 | 2020-2024 | Prolastin-C Liquid |
| Medtronic USA, INC. | $80.00 | 2019 | |
| Abbvie INC. | $78.88 | 2021-2025 | Dalvance |
| Pfizer INC. | $75.29 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $67.18 | 2023-2024 | Purified Cortrophin Gel |
| Axsome Therapeutics, INC. | $64.06 | 2023 | Sunosi |
| Amgen INC. | $56.74 | 2023 | Tezspire |
| Baxter Healthcare | $50.72 | 2022 | |
| Advanced Respiratory, INC | $43.61 | 2019-2020 | |
| Electromed, INC. | $35.96 | 2023-2024 | Smartvest |
| Inspire Medical Systems, INC. | $33.84 | 2024 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $30.14 | 2023 | Aralast |
| Bayer Healthcare Pharmaceuticals INC. | $29.23 | 2022 | |
| Janssen Pharmaceuticals, INC | $24.85 | 2019 | |
| Merck Sharp & Dohme LLC | $22.39 | 2024 | Zerbaxa |
| Gilead Sciences, INC. | $19.98 | 2021 | |
| Shionogi INC | $19.97 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $19.52 | 2021 | |
| Genentech USA, INC. | $16.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Bin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.